drugset / Trial / NCT04395612

Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer

NCT04395612

Phase 2 Unknown 38 enrolled Chongqing University Cancer Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Clinical Proof-of-concept Study Evaluating Efficacy and Safety of ZL-2306 (Niraparib) Combined With Brivanib or Toripalimab in Patients With Metastatic, Recurrent, and Persistent Cervical Cancer

Timeline

Start
2020-05-08
Primary completion
2022-04-01
Completion
2022-07-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivanib Small molecule 400 mg Oral
Subject Niraparib Small molecule 200 mg Oral
Subject Toripalimab Monoclonal antibody 240 mg Intravenous

Indications